NFE2L2 and prostate carcinoma: Interestingly, Satoshi Endo and colleagues reported a higher NRF2 nuclear expression in cabazitaxel-resistant prostate cancer 22Rv1/Cab-R cells compared to the cabazitaxel sensitive 22Rv1 cells [146].